Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPN-810 in children with impulsive aggression and ADHD
NCT01364662Phase 2Completed
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Jun 2011
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of molindone in intermittent explosive disorder (IED) (4 arms), sponsored by Supernus Pharmaceuticals, Inc. Primary endpoint: Retrospective-Modified Overt Aggression Scale. Started Jun 2011; status: completed.
02
Drugs
molindone
03
Conditions
intermittent explosive disorder (IED)
Beyond the preview
Go deeper on NCT01364662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01364662.